Pyrrolidinyl di-carboxylic acid derivatives as metabotropic glutamate receptor agonists
AssigneeEli Lilly and Company
InventorsJames A. Monn, Darryle D. Schoepp, Matthew J. Valli
Life of this patent
Estimating the term…
Abstract
The present invention provides novel compounds that affect certain excitatory amino acid receptors, and are useful in the treatment of neurological disorders and psychiatric disorders.
Claims30
A compound of the formula ##STR13## where R.sup.1 and R.sup.2 are independently carboxylic acid or 5-tetrazolyl, or a pharmaceutically acceptable salt or solvate thereof.
A method for treating a neurological disorder in a mammal which comprises administering to a mammal in need thereof a pharmaceutically-effective amount of a compound of the formula ##STR14## where R.sup.1 and R.sup.2 are independently carboxylic acid or 5-tetrazolyl, or a pharmaceutically acceptable salt or solvate thereof.
A pharmaceutical formulation comprising an effective amount of a compound of the formula ##STR15## where R.sup.1 and R.sup.2 are independently carboxylic acid or 5-tetrazolyl, or a pharmaceutically acceptable salt or solvate thereof, in combination with one or more pharmaceutically acceptable carriers, diluents, or excipients therefor.
Dependencies are inferred from the claim text.